Related content

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

By Guo Feng   Letrent Stephen   Munster Pamela   Britten Carolyn   Gelmon Karen   Tolcher Anthony   Sharma Amarnath  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 97-109

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors

By Müller V.  

American Journal of Cancer, Vol. 2, Iss. 2, 2003-01 ,pp. : 77-86

Adis International

Access to resources Recommend Favorite

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

By Yan Zhao   Zhu Zhongling   Li Kai   Chen Peng   Wang Liuchun   Huang Chun   Xue Jinhuai   Liu Meijun  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 955-961

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

By Hurwitz Herbert   Cohen Roger   McGovren J.   Hirawat Samit   Petros William   Natsumeda Yutaka   Yoshinari Tomoko  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 139-147

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

By Mross Klaus   Niemann Bernward   Massing Ulrich   Drevs Joachim   Unger Clemens   Bhamra Rupinder   Swenson Christine  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 514-524

Springer Publishing Company

Access to resources Recommend Favorite